Article
Public (all visitors)
Fast-moving Regeneron eyes summer clinical trial for COVID-19 antibody cocktail therapy
FierceBiotech
2020
During the 2018 outbreak of Ebola, Regeneron quickly developed a promising monoclonal antibody triplet therapy that’s now under review by the FDA. Now, amid the ongoing coronavirus pandemic, the biotech is at it again, planning to advance a antibody cocktail into the clinic by early summer.
Curated by
FoundryBase
Visibility
Public (all visitors)
Saved in
2 chunks
Kind
Article
Response
Browse more
View All ArticlesAdjacent discoveries
Keep moving through nearby material.
Related resources
With chunks in common.
A drug that cools the body’s reaction to Covid-19 appears to save lives
2020
Appears in 1 shared chunk
Inexpensive steroids reduce deaths of hospitalized Covid-19 patients, WHO analysis confirms
2020
Appears in 1 shared chunk
Nature: The race to make COVID antibody therapies cheaper and more potent (Oct. 2020)
2020
Appears in 1 shared chunk
As monoclonal antibody Covid-19 treatment arrives, hospitals scramble to solve logistical and ethical challenges
2020
Appears in 1 shared chunk
More related content
With shared categories.
HPV vaccine reduced cervical cancer rates by 87% in women, study finds - CNN
2021
Shares 9 topic signals
It took a pandemic, but the US finally has (some) centralized medical data | MIT Technology Review
2021
Shares 9 topic signals
FDA grants historic approval to Alzheimer’s drug designed to slow cognitive decline
2021
Shares 9 topic signals
Scientists Are Working on mRNA Vaccines for HIV, Flu, Cancer and More - POZ
2021
Shares 9 topic signals
First vaccine to fully immunize against malaria builds on pandemic-driven RNA tech - The Academic Times
2021
Shares 9 topic signals
The same covid-19 mutations are appearing in different places | Graphic detail | The Economist
2021
Shares 9 topic signals
Contribute to FoundryBase
Found something worth adding?
Sign in to suggest resources and start building your own collection.